Schedule 13G Filing for Agios Pharmaceuticals, Inc.

A Schedule 13G filing was submitted by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. regarding their beneficial ownership of common stock in Agios Pharmaceuticals, Inc. The filing indicates that these entities collectively own 5.2% of the company's common stock, with Paradigm BioCapital International Fund Ltd. owning 4.6% individually. The shares are held directly by the Fund and a separately managed account managed by Paradigm BioCapital Advisors LP. The filing also includes a joint filing agreement, confirming that the entities are jointly filing the Schedule 13G. The event date for this filing is August 21, 2025, and it was submitted on August 28, 2025.